Cargando…
Immunoglobulines hyperimmunes anti-SARS-CoV-2, un choix stratégique urgent
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Academie nationale de medecine
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234932/ https://www.ncbi.nlm.nih.gov/pubmed/32834024 http://dx.doi.org/10.1016/j.banm.2020.05.041 |
| _version_ | 1783535866370588672 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7234932 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Academie nationale de medecine |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72349322020-05-19 Immunoglobulines hyperimmunes anti-SARS-CoV-2, un choix stratégique urgent Bull Acad Natl Med Article Academie nationale de medecine 2020-07 2020-05-19 /pmc/articles/PMC7234932/ /pubmed/32834024 http://dx.doi.org/10.1016/j.banm.2020.05.041 Text en © 2020 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Immunoglobulines hyperimmunes anti-SARS-CoV-2, un choix stratégique urgent |
| title | Immunoglobulines hyperimmunes anti-SARS-CoV-2, un choix stratégique urgent |
| title_full | Immunoglobulines hyperimmunes anti-SARS-CoV-2, un choix stratégique urgent |
| title_fullStr | Immunoglobulines hyperimmunes anti-SARS-CoV-2, un choix stratégique urgent |
| title_full_unstemmed | Immunoglobulines hyperimmunes anti-SARS-CoV-2, un choix stratégique urgent |
| title_short | Immunoglobulines hyperimmunes anti-SARS-CoV-2, un choix stratégique urgent |
| title_sort | immunoglobulines hyperimmunes anti-sars-cov-2, un choix stratégique urgent |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234932/ https://www.ncbi.nlm.nih.gov/pubmed/32834024 http://dx.doi.org/10.1016/j.banm.2020.05.041 |